← All trials
NCT04543812
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 14, 2020
- Primary completion
- Nov 30, 2021
- Completion date
- Mar 31, 2022
- First posted
- Sep 10, 2020
- Last posted
- Dec 3, 2020
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Panion & BF Biotech Inc.Lead sponsor
- Taipei Veteran General hospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.